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Abstract
Background: Mycoplasmas are cell wall-less bacteria which encode a minimal set of proteins. In
Mycoplasma hominis, the genes encoding the surface-localized membrane complex P60/P80 are in
an operon with a gene encoding a cytoplasmic, nucleotide-binding protein with a characteristic
Histidine triad motif (HinT). HinT is found in both procaryotes and eukaryotes and known to
hydrolyze adenosine nucleotides in eukaryotes. Immuno-precipitation and BIACore analysis
revealed an interaction between HinT and the P80 domain of the membrane complex. As the
membrane anchored P80 carries an N-terminal uncleaved signal peptide we have proposed that the
N-terminus extends into the cytoplasm and interacts with the cytosolic HinT.
Results: Further characterization of P80 suggested that the 4.7 kDa signal peptide is protected
from cleavage only in the membrane bound form. We found several proteins were released into
the supernatant of a logarithmic phase mycoplasma culture, including P80, which was reduced in
size by 10 kDa. Western blot analysis of recombinant P80 mutants expressed in E. coli and differing
in the N-terminal region revealed that mutation of the +1 position of the mature protein (Asn to
Pro) which is important for signal peptidase I recognition resulted in reduced P80 secretion. All
other P80 variants were released into the supernatant, in general as a 74 kDa protein encompassing
the helical part of P80. Incubation of M. hominis cells in phosphate buffered saline supplemented
with divalent cations revealed that the release of mycoplasma proteins into the supernatant was
inhibited by high concentrations of calciumions.
Conclusions: Our model for secretion of the P80 protein of M. hominis implies a two-step
process. In general the P80 protein is transported across the membrane and remains complexed
to P60, surface-exposed and membrane anchored via the uncleaved signal sequence. Loss of the
4.7 kDa signal peptide seems to be a pre-requisite for P80 secretion, which is followed by a
proteolytic process leading to a helical 74 kDa product. We propose that this novel form of two-
step secretion is one of the solutions to a life with a reduced gene set.
Background
The contact of a pathogenic bacterium with its eukaryotic
host provokes a multitude of reactions. A prerequisite for
successful infection with the host is the cytadhesion of the
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bacterium generally mediated by surface localized pro-
teins [1]. Besides adhesion, pathogens like Listeria, Yers-
inia and even some of the mycoplasmas are able to invade
the host cells [2-4]. An intracellular localization is obvi-
ously a privileged niche, as the bacteria are well protected
from the immune system. Moreover, bacteria not only
remain concealed, but have evolved strategies for an
attack on the eukaryotic cell. In secreting virulence factors,
such as antigenic or toxic proteins, bacteria can mislead
the host immune response or damage the colonized tissue
[5-7].
The large majority of exported proteins possess an N-ter-
minal signal sequence [8]. Most signal sequences are rec-
ognized by the Sec-dependent protein translocation
complex (translocase), which mediates membrane trans-
location of unfolded precursors [9]. The signal sequences
of proteins predicted to be recognized by type I signal
peptidases are composed of a short, positively charged
amino-terminal region (n-region), a central hydrophobic
region (h-region) and a more polar carboxyl region (c-
region) containing the cleavage site [10]. The signal pep-
tides present in pre-lipoproteins additionally contain a
well-conserved lipobox with an invariant cysteine residue
that is lipid-modified prior to precursor cleavage by signal
peptidase II [11,12]. Cleavage of the signal peptide is not
required for translocation of the proteins through the
membrane, but is generally the final step in processing
[13]. However, some precursors remain membrane
bound because of an uncleaved hydrophobic signal pep-
tide and diffuse laterally from the translocase [14].
In the last few years, computer programs such as PSORT-
II, PSORT-B, ExProt and SignalP have been developed to
facilitate the identification of putative secreted proteins
[15-18]. Comparison of proteomes of Gram-negative bac-
teria, Gram-positive bacteria and Archaea using ExProt
revealed that the fraction of putative secreted proteins
ranged from 8% in the archaeal bacterium Methanococcus
jannaschii to 37% in the mollicute Mycoplasma pneumoniae
[17]. Analysis of the exported proteins of Bacillus subtilis
found that only 50% of the secreted proteins were
detected by genomic prediction, indicating that pro-
teomic analyses of secreted proteins (the secretome) are
necessary for a comprehensive definition of all secreted
proteins [19].
Only a handful of mollicute genomes have been decoded,
but no analyses of their secretomes have been conducted.
A secreted protein, probably processed by the classical
mechanism described above, has been characterized in
the swine pathogen M. hyopneumoniae. P102 is encoded as
a precursor protein carrying a type I signal sequence and is
found exclusively in the extra-cellular milieu suggesting
cleavage by signal peptidase I. The expression of secreted
P102 is coupled to that of the surface-exposed cilium
adhesin P97, which seems to represent a new variant of
processed surface antigens. P97 is derived from a 126 kDa
precursor protein by cleavage at amino acid residue (aa)
195. The cleaved 22 kDa N-terminal fragment, which car-
ries an uncleaved type I signal sequence is found embed-
ded in the membrane, in the cytoplasm and in a soluble
form in the supernatant, whereas the mature P97, pro-
posed to be membrane bound, is the target of complex
proteolytic cleavage, which leads to the subsequent
release of some fragments into the supernatant [20,21].
The lipoprotein MALP-404 of M. fermentans is a further
example of a surface-localized protein undergoing prote-
olysis after reaching its target. Site-specific cleavage leads
to the generation of the membrane bound immune-stim-
ulatory lipopeptide MALP-2 and the release of the remain-
der (the RF fragment) in a soluble form into the
supernatant [22].
In M. hominis, which is mainly found as a commensal in
the urogenital tract, but has also been associated with
human urogenital tract infections [23,24], two variants of
a cell-surface protein exist, one a lipoprotein (P120) and
a homologous P120' without a lipid anchor, but contain-
ing an uncleaved N-terminal signal sequence for type I sig-
nal peptidases [25]. Recently we identified a gene locus
coding for a surface-localized protein complex composed
of a 60 kDa lipoprotein (P60) tightly bound to an 80 kDa
precursor protein (P80) with an uncleaved type I signal
sequence [26]. We have proposed that the uncleaved N-
terminus extends into the cytoplasm and thus mediates an
interaction with the concomitantly expressed cytoplasmic
HinT protein. HinT is found in prokaryotes and eukaryo-
tes and in the latter is known to function as an adenosine
nucleotidyl-hydrolase [27].
The data in this paper suggest that the signal peptidase I
recognition site is protected in the membrane bound form
of P80, but is accessible as the first step in the release of
the helical part of P80 into the cell culture supernatant, a
process which is accompanied by a decrease in size of 10
kDa.
Results
To confirm our hypothesis that the P60/P80 membrane
complex interacts with the cytoplasmic HinT via the
uncleaved N-terminus of P80 that extends into the cyto-
plasm, we set out to express different fragments of the P80
protein to map the domain of P80 that interacted with
HinT. As mycoplasmas use TGA as a tryptophan codon,
rather than a stop codon as in E. coli, the TGA codons were
mutated to TGG to allow expression. However, even
though we mutated all TGA codons to TGG in the hitA
gene, which encodes P80, we were not able to express and
purify P80 peptides with an intact N-terminus. While P80-BMC Microbiology 2004, 4:46 http://www.biomedcentral.com/1471-2180/4/46
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2, the C-terminal region of P80 from AA 320 to AA 713,
was stably expressed in E. coli, P80-NT, the initial 21AA of
the N-terminus, and P80-1, the N-terminal portion of P80
from AA 1 to AA 326, were degraded at the N-terminus
during purification (Figure 1). Purification of the 2.6 kDa
P80-NT fused to dihydrofolate reductase (DHFR) led to
complete loss of the P80 region. As P80 NT did not con-
tain the cleavage site of the signal peptidase I this proteol-
ysis may be due to the presence of further processing
signals within the first 21 AA of P80. The isolation of P80-
1 revealed rapid degradation of the 40.7 kDa peptide with
loss of 5, 6 and 8 kDa portions of the protein and loss of
the poly His tag. Expression of the whole rP80 polypep-
tide chain (AA 1–713) resulted in a protein about 10 kDa
smaller than expected, which lacked the poly His tag
(depicted as a gray striped box in Figure 1). The conjecture
that N-terminal degradation occurs was supported by
Western blot analyses with anti-tetra His antibodies in
which the purified forms of P80-1 and rP80 were not
detectable (data not shown).
Physical map and expression profile of recombinant P80 peptides Figure 1
Physical map and expression profile of recombinant P80 peptides. The 713 AA polypeptide chain of the P80 precur-
sor protein is schematically represented by an alignment of proposed α helical and surface localized regions. The expressed 
regions in the different P80 variants are shown below in gray flanked by the amino acid numbers corresponding to the position 
within the P80 precursor. The striped boxes represent the fused poly His tags, colored in black or gray, respectively, depend-
ing on their presence or absence after purification of the recombinant protein. P80-NT was expressed as a fusion with dihy-
drofolate reductase (DHFR). In the Western-blot analysis shown below, lysates (lane 1) and purified P80 variants (lane 2) have 
been immunostained with an anti-His4-antibody (P80-NT), or the P80-specific monoclonal antibodies NB12 (P80-1) or LF8 
(P80-2, rP80).
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As conventional protease inhibitors had no effect on the
P80 degradation (data not shown) and as type I signal
peptidases share the unusual feature of being resistant to
general inhibitors of the four other peptidase classes [10]
we speculated that the degradation observed in the
expressed rP80 may be in fact the result of physiological
processing in E. coli.
Analysis of the mechanism of rP80 processing
In order to test the hypothesis that the degradation of
rP80 is mediated by E. coli signal peptidase I, we charac-
terized different mutants of the recombinant P80 protein
according to their processing in E. coli. Using PCR, we con-
structed clones expressing the mature P80 protein without
the 44 AA signal peptide (∆SP) and an 89 AA N-terminal
truncated P80 protein, which corresponds to the pro-
posed helical, surface-localized part of P80 (Helic.). As
the absence of proline at the +1 position of the mature
protein is consistent with the observation that the SPase I
of E.coli was inhibited by recombinant precursor proteins
having a proline residue at this position [12], we gener-
ated a P80 precursor with an Asn to Pro mutation (N/P)
at the (+1) position in the mature protein expecting a
reduced or complete inhibition of signal peptide cleavage
(Figure 2-A). Western-blot analysis of the heterologous
expressed P80 variants in whole E. coli lysates revealed
that a marked reduction of P80 processing was indeed
observed for the (N/P) mutant, while the sizes of secreted
P80 variants corresponded to that of the helical variant
(Figure 2-B). Small amounts of rP80 precursor were only
observed in the lysate after prolonged exposure in immu-
nostaining with the P80-specific mAb LF8 (data not
shown). All variants, with the exception of the N/P
mutant, were transported across the inner and the outer
membranes and were of nearly the same size as the
secreted 74 kDa peptide of the P80 protein found in M.
hominis (Fig. 2; FBG, supernatant). In the case of P80-
(∆SP) and P80-(Helic.), the two variants lacking signal
sequences as translocation signals, this transport may be
mediated by an alternative, Sec-independent export
mechanism.
P80 secretion in Mycoplasma hominis
The data suggest that the recombinant P80 processing in
E. coli is signal peptidase I-mediated and therefore we
investigated the protection of the signal peptidase I recog-
nition site of P80 in Mycoplasma hominis [26]. Therefore,
we analyzed the cellular proteins and the proteins in the
culture supernatant in a mycoplasma culture in early-,
mid- and stationary growth phases. To ensure that no via-
ble cells were left in the supernatant we checked the sepa-
ration efficiency by determining the titres of mycoplasmas
in the supernatant and the original culture. The titres in
the supernatants were 0.01% to 0.13% of those of the
original cultures, demonstrating that the Western blot
analysis would not be confounded by inclusion of cellular
proteins in the supernatants (data not shown).
As might be expected the stationary phase culture con-
tained several proteins that might be released from lysed
cells, including P50, P60, OppA and cytoplasmic proteins
such as P55 (Figure 3-A). However, the same membrane
proteins were found in the mid-logarithmic phase sug-
gesting release of these proteins from living cells into the
supernatant. Indeed, the amount of the cytoplasmic P55
was reduced in this culture suggesting that in mid-loga-
rithmic phase few proteins from lysed cells are present.
Lipoproteins, such as P50 and P60 were also found in the
supernatant of a mycoplasma culture at the beginning of
logarithmic growth (early), whereas OppA was absent. In
general, immunostaining of P80 was weak in samples
derived from the supernatant of a broth culture. This
might be due to a masking of P80 by albumin, which was
present in high concentrations in the culture medium and
of similar size as the secreted P80 protein.
Interestingly, the P80 protein was the only one of the pro-
teins analyzed that had a decreased size in the superna-
tant. To exclude the possibility that the reduction in size
was simply a result of the large amount of albumin in the
culture medium, we purified P80 from the supernatant of
a culture in mid logarithmic growth using affinity chro-
matography. In addition we analyzed P60 as a control. As
shown in Figure 3-B, the secreted P80 peptide was
decreased in size by approximately 10 kDa in comparison
to the cellular form, whereas P60 remained unaltered. A
degree of processing of the P80 precursor was detectable,
with several distinct P80 staining bands between 80 and
74 kDa, running through distinct steps of degradation as
shown for the recombinant P80-1 peptide (see Figure 1).
As the activity of proteases often depends on the presence
of divalent cations, we examined the secretion of myco-
plasma proteins in the presence or absence of divalent cat-
ions. Mycoplasma cells were incubated for 1 h at 37°C in
phosphate buffered saline (PBS) supplemented with up to
5 mM magnesium or calcium chloride, or chelating agents
as EDTA and EGTA. The addition of divalent cations did
not increase the processing of P80 (data not shown). As
the presence of 5 mM calcium ions resulted in a complete
disappearence of P80 from the supernatant we examined
the release of mycoplasma proteins from cells following
stepwise addition of calcium ions at concentrations of 0 to
5 mM (Figure 4). Silver staining of the cell and superna-
tant preparations revealed that only a few proteins were
released in the supernatant whereas most proteins
remained cell-embedded (Figure 4-A). Increasing the cal-
cium chloride concentration to more that 1.3 mM led to a
dramatic reduction in secretion. All the antigens analyzed,BMC Microbiology 2004, 4:46 http://www.biomedcentral.com/1471-2180/4/46
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with the exception of OppA, were found in the
supernatant, even the cytoplasmic proteins P55 and elon-
gation factor Tu (EF-Tu) (Figure 4-B).
The cytoplasmic proteins that were detected in the super-
natant were not released from lysed cells as the titres of the
cultures remained the same throughout the experiment
(data not shown). These findings are in accordance with
those of Antelmann and coworkers, who found several
cytoplasmic proteins, such as elongation factor G (EF-G)
and arginase (RocF) as to be components of the secretome
of Bacillus subtilis [19].
Western blot analysis of the P80 variants Figure 2
Western blot analysis of the P80 variants. A. The P80 variants are represented by alignments of their proposed α helical 
regions and hydropathy profiles. B. After cultivating the different P80 clones for 2–5 h in LB-Amp medium proteins in the 
supernatant (after 5 h cultivation), the periplasmic fraction and the cell pellet (after 2 h cultivation) were separated by 9.5% 
SDS-PAGE and subjected to Western blot analysis using the P80 specific monoclonal antibody LF8. The samples correspond to 
10 µl of the recombinant P80 (rP80) culture, 1 ml of P80Asn45Pro (N/P) culture, 10 µl of the helical P80 variant (Helic.) culture 
and 1 µl culture of the culture of the P80 variant without signal peptide (∆SP). Samples from the culture supernatant were 
obtained from 30 µl (rP80), 0.8 ml (N/P), 0.2 ml (Helic.) and 60 µl (∆SP) of media, and periplasmic proteins from 0.4 ml 
(rP80), 2 ml (N/P), 0.1 ml (Helic.) and 2 ml (∆SP) of cultures. Additionally, lysate from 50 µl of culture and proteins from 250 
µl of cell culture supernatant of M. hominis (strain FBG) were used. Marker, SeeBlue (Invitrogen, Germany).
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Increasing the concentration of calcium ions to more than
0.6 mM CaCl2inhibited a release of most mycoplasma
proteins from the cells (Figure 4-B, lane 4). Of the pro-
teins analyzed, only EF-Tu was found in the supernatant
of a sample treated with 1.3 mM CaCl2 (Fig. 4-B, lane 3).
Thus the surface-localized P80 protein, normally com-
plexed with the P60 lipoprotein in the membrane,
appears to be released into the extra-cellular environment
as a 74 kDa cleavage product. Our model of processing
describes the initial cleavage of the 4.7 kDa signal peptide
by a type I signal peptidase, followed by further degrada-
tion by unknown mechanisms, leading to a stable 74 kDa
peptide.
Discussion
The data presented here indicate that the membrane pro-
tein P80 of Mycoplasma hominis is a representative of a new
group of proteins in the Mollicutes. P80 occurs as a precur-
sor protein (complexed with the lipoprotein P60)
anchored in the membrane and exposed on the surface,
and is also released into the extra-cellular environment. As
P80 and P60 are concomitantly expressed and both com-
plexed in the membrane fraction it is likely that the
Proteins released in the culture supernatant of Mycoplasma hominis Figure 3
Proteins released in the culture supernatant of Mycoplasma hominis. A. Western blot analysis of the proteins from 
150 µl of supernatant and cells from 15 µl of culture, immunostained with the membrane protein specific monoclonal antibod-
ies BG11 (OppA), LF8 (P80) and CG4 (P60), BG2 (P50), and the cytoplasmic protein specific monoclonal antibody AH10 (P55). 
B. Western blot analysis of P60 and P80 of M. hominis lysate (Lys.) from 15 µl of culture and of two different fractions of the 
purified P60 (P60SN) and P80 (P80SN) from the supernatant of a cell culture using sepharose-coupled antibodies LF8 (P80) or 
CG4 (P60).
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soluble P80 variant is derived from the membrane bound
precursor. Interestingly, the findings from the heterolo-
gous expression of different P80 mutants in E. coli suggest
that release of P80 is initiated by cleavage of the N-termi-
nal type I signal sequence, followed by amino-terminal
proteolysis by an unknown mechanism, leading to a sta-
ble P80 peptide with a predicted helical structure in the
supernatant.
As the genome of M. genitalium, the smallest known self-
sufficient organism, lacks a gene for the type I signal pepti-
dase [30] it was initially speculated that this enzyme may
be absent in the Mollicutes, despite the fact that several
proteins with type I-signal sequences had been identified
[10,25]. However signal peptidase I genes have been
found in the genomic sequences of Mycoplasma gallisepti-
cum  (MGA_1091) and M. pulmonis (MYPU_6300)
[31,32].
The release of mycoplasmal proteins into the extra-cellu-
lar milieu may follow different pathways to those
described previously for other bacteria. While the exclu-
sive detection of P102 of M. hyopneumoniae in the extra-
cellular matrix suggests that the intrinsic N-terminal type
I signal peptide is immediately cleaved after translocation
of the precursor through the membrane, as would be
expected from current knowledge of the classical protein
secretion pathway, the precursor proteins P80 and P120'
of M. hominis are attached to the membrane without being
processed or released into the supernatant [21,25,26].
The later release of a surface-localized peptide is described
here for the first time. Davis and Wise described site-spe-
cific proteolysis of the lipid-anchored MALP-404 of M. fer-
mentans  that leads to the generation of the immune-
stimulatory lipopeptide MALP-2 and showed that the
residual RF peptide was soluble and was released into the
Secreted antigens of Mycoplasma hominis Figure 4
Secreted antigens of Mycoplasma hominis. M. hominis cells from a mid-logarithmic phase culture were incubated for 1 h at 
37°C in PBS containing 0 to 5 mM CaCl2 as indicated. Proteins in 0.4 ml of culture supernatants and cell pellets from 0.02 ml of 
cultures were separated in 9.5 % polyacylamide gels and silver stained (A.) or Western blotted (B.) using the monoclonal anti-
bodies BG11 (OppA), LF8 (P80) and CG4 (P60), AH10 (P55), BG2 (P50) or KD2 (EF-Tu). The predominant band in the super-
natant without calcium ions is recognized by the anti-P80 antibody LF8. Molecular Weight Marker: See Blue Plus 2 (Invitrogen, 
Karlsruhe, Germany).
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supernatant [22]. Processing of the P97 cilium adhesin
precursor, P126, of M. hyopneumoniae appears to be quite
complex. The precursor protein P126, which carries a type
I signal sequence with a cleavage site between AA 31 and
AA 32, is predominantly cleaved between AA 194 and AA
195, suggesting that the SP-I signature may be essential
only for the translocation of the whole precursor protein
across the membrane. The cleavage products P22 and P97
both remain closely associated with the membrane. While
P97 is generally subjected to further site-directed proteol-
ysis, leading to the release of peptides into the extra-cellu-
lar milieu, further processing of P22 occurs to be strain
dependent [21].
Release of proteins into the surroundings of a myco-
plasma cell should lead to an immediate alteration of the
cell surface architecture and, as most membrane proteins
are targets for the host immune response [33,34], may
also interfere with the host effector response. Type II
secreted proteins appeared to be typically associated with
non-invasive organisms colonizing mucosal surfaces,
such as Mycoplasma hominis, and are considered to be
required for the establishment of an infection at these
sites. Recently in Legionella pneumophila a type II protein
secretion system was characterized as a virulence factor
linked to an intracellular infection [35].
P80 has significant similarity with two protein sequences,
a hypothetical protein of M. pulmonis (MYPU_0060;
gi15828477) the gene of which is followed by P60
(MYPU_0070) and HinT (MYPU_0080) gene homo-
logues, and a rhoptry protein of Plasmodium yoelii yoelii
(gi23481286). Rhoptry proteins are released during host
cell invasion by apicomplexans [36].
As P80 interacts with HinT, a cytoplasmic protein found
in all kingdoms, which in eukaryotes hydrolyses AMP
derivatives and in yeasts functions as a regulator of an
RNA polymerase II domain [27], a further scenario is
imaginable: We do not know which factors promote the
processing of the surface-exposed P80 protein. However,
release of the helical P80 peptide is accompanied by the
retention of the signal peptide I in the membrane. Some
signal peptides have been found to leak back into the cell
where they bind to proteins, such as the Ca2+-binding cal-
modulin [37], or are presented to the immune system
[38], where they probably have a secondary signaling
function distinct from their role in targeting [39]. Our
results indicate that an increase in calcium ions prevents
secretion of mycoplasma proteins. Thus, an extra- or intra-
cellular stimulus – such as a local variation in the concen-
tration of Ca2+ ions – may activate the signal peptidase
induced processing of the membrane bound P80 protein.
This would lead to a soluble P80-helix and the membrane
anchored signal peptide. After loss of the transmembrane
spanning C-terminal amino acids or due to a leakage of
the whole signal sequence (as described above) the signal
peptide could reach the cytoplasm where an interaction
with HinT may be a further step in modulating or promot-
ing cellular processes such as growth or activation of gene
expression, a process we are currently investigating.
Conclusions
The data presented here clearly demonstrate that P80 is a
secreted antigen of Mycoplasma hominis. This is, to our
knowledge, the first description of secreted protein with a
type I signal sequence that is stably embedded in the
membrane as precursor protein and, as we propose as a
model of secretion, is subsequently released from the
membrane into the supernatant after signal peptidase I
cleavage. As in other mycoplasmas several proteins have
been shown to either possess an uncleaved signal
sequence or to be further processed after anchoring in the
membrane, this may be a common phenomenon in myc-
oplasmas. Because of their minimal coding capacity, myc-
oplasmas may have evolved a strategy to use secretory
proteins in a dual role, as surface localized proteins in the
membrane for cell surface architecture, and, in response
to a change in the environment, as a soluble protein
released from the cell surface.
Methods
Cloning and expression of rP80 and P80 mutants
The P80 protein encoding region (ACC Z29068) of Myco-
plasma hominis strain FBG was amplified by PCR [26]
using oligonucleotides (MWG Biotech, Ebersberg, Ger-
many) that change the mycoplasma TGA tryptophan
codon to TGG. Fragments were either directly cloned for
the expression of distinct P80 regions or fused by SOE
(splicing by overlap extension)-PCR [40]. To facilitate
cloning of PCR products [41], restriction sites were
inserted in the primer sequence without changing the
amino acid sequence. P80 variants with mutations in the
N-terminal part of P80 were generated by PCR by ampli-
fying the region encoding the helical portion of P80
(Helic., AA 90–713), amplifying a fragment encoding the
mature P80 polypeptide (∆SP, AA 45–713), and mutating
the asparagine codon at position +1 of the mature protein
to a proline codon (N/P).
Amplicons were cut at the restriction sites within the
primers and ligated in-frame into the expression vector
pQE30 (Qiagen, Hilden, Germany). To express the P80 N-
terminus (AA 1–21) as a fusion protein with dihydro-
folate reductase and a poly His-tag, we ligated the respec-
tive RcaI/BglII restricted amplicon in frame into the NcoI/
BglII restricted plasmid pQE60 and inserted the BamHI/
BglII restricted DHFR-fragment of pQE40 in the BglII site
of the plasmid pQE60-P80 NT. Plasmids were propagated
in DH5αF' for constitutive expression [41].BMC Microbiology 2004, 4:46 http://www.biomedcentral.com/1471-2180/4/46
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Cells from a mid-logarithmic phase culture in LB broth
(Gibco BRL, Life Technologies Inc., Gaithersburg, Md.)
containing ampicillin (100 µg/ml) were harvested by
centrifugation (20,000 × g, 30 min, 4°C). In the secretion
assay, the pelleted cells and supernatant, which was con-
centrated by lyophilizing, were subjected to Western blot
analysis. The recombinant peptides P80-NT and P80-2
were purified by Ni-NTA chelation according to the man-
ufacturer's protocol, while rP80 and P80-1 were purified
with the Sepharose-coated P80-specific antibodies LF8
and NB12 as described by Henrich et al. [34].
Sequence analysis
The analysis of DNA and protein sequences and the
design of oligonucleotides were facilitated by use of the
software package Lasergene (DNASTAR Inc. 1996, Madi-
son, Wisc.). The integrity of the different plasmid
sequences was confirmed by analysis on an ABI sequencer
using the method of Sanger [42].
Mycoplasma culture, osmotic lysis and secretion assays
Mycoplasma hominis strain FBG was cultivated in PPLO
broth supplemented with arginine from frozen stocks of a
mid-logarithmic phase broth culture as described previ-
ously [43]. The titer of the broth culture was determined
by the measuring the number of color changing units
(CCU) [34]. For protein secretion analyses, the myco-
plasma cells from early- to mid-logarithmic phase cultures
were harvested by centrifugation (20,000 × g, 10 min,
4°C), and the cell pellets and supernatants were subjected
to Western blot analysis. Alternatively, cell pellets derived
by low speed centrifugation (10,000 × g, 10 min, 4°C)
were re-suspended in phosphate-buffered saline (PBS;
120 mM NaCl, 5 mM KCl, 20 mM Tris-HCl, pH 7.5) con-
taining 5.0, 2.5, 1.25, 0.63, 0.31 or 0.00 mM CaCl2 and
incubated at 37°C for 60 min. Soluble proteins were then
separated from insoluble material by centrifugation
(15,000 × g, 15 min, 4°C), and all samples analyzed by
Silver staining [44] and Western blotting.
Western blot analysis
Proteins were separated in 9.5% polyacrylamide gels [45],
transferred to nitrocellulose (Schleicher and Schüll, Das-
sel, Germany) with a semidry blotting apparatus (Phase,
Mölln, Germany) [46], and immunostained as described
by Henrich et al. [34] using the monoclonal antibodies
BG11 (anti-OppA), BG2 (anti-P50), LF8 (anti-P80), or
CG4 (anti-P60), all of which are directed against mem-
brane proteins, and AH10 (P55) and KD2 (EF-Tu), which
are directed against proteins primarily located in the
cytoplasm.
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